-
ClinBrain and WCH Establish Joint Laboratory for Geriatric Information Platform
•
Shanghai-based ClinBrain, a clinical data repository (CDR) and medical big data services provider, together with the National Clinical Research Center for Geriatric Diseases (WCH), announced the establishment of a “joint laboratory of geriatric information platform.” The two will work together on clinical research applications, the construction of a high-quality clinical…
-
Wuhan YZY Biopharma Files for IPO on Hong Kong Stock Exchange
•
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and drug immunotherapies, has made an initial public offering (IPO) filing to the Hong Kong Stock Exchange. Product Pipeline and R&D FocusYZY Bio, focused on the research and development (R&D) and industrialization of bispecific antibodies (BsAb),…
-
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
•
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection) in Chinese adults with relapsed/refractory follicular lymphoma (r/r FL) and relapsed/refractory mantle cell lymphoma (r/r MCL) at the 64th American Society of Hematology (ASH) annual meeting. Efficacy and Safety in Relapsed/Refractory Follicular LymphomaIn the pivotal…
-
4B Technologies Raises RMB 100M in Pre-Series B Financing Round
•
China-based 4B Technologies Investments Ltd, a biotech focused on central nervous system (CNS) drug development, reportedly raised upwards of RMB 100 million (USD 14.3 million) in a Pre-Series B financing round. Dachen Capital led the round, which included contributions from Huaxi Investment, FangSheng Capital, ZGC Co-Innovation Fund, and Tao Capital,…
-
Gaush Meditech IPOs on Hong Kong Stock Exchange at HKD 21.4 per Share
•
China-based Gaush Meditech Ltd reportedly made an initial public offering (IPO) at the Hong Kong Stock Exchange, priced at HKD 21.4 (USD 2.75) per share. That amounts to an HKD 672 million (USD 86.4 million) take-home. Financial PerformanceGaush generated RMB 1.298 billion (USD 186 million) and RMB 578 million (USD…
-
Northeast Pharmaceutical Fined RMB 133M for Monopoly Selling
•
Northeast Pharmaceutical Co., Ltd (SHE: 000597) was fined RMB 133 million (USD 19m) by the Liaoning Administration for Market Regulation. The China-based firm was investigated by the bureau in November 2019, when the company was suspected of monopoly selling of levocarnitine active ingredients from November 2018 to June 2019. Investigation…
-
Dizal Pharma Presents Golidocitinib Data at ASH Annual Meeting
•
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented the latest clinical data on golidocitinib (DZD4205) at the 64th American Society of Hematology (ASH) annual meeting. Global Multi-Center Phase I/II StudyA global multi-center Phase I/II study for golidocitinib in recurrent refractory peripheral T-cell lymphoma (r/r PTCL) included a total of 51…
-
HitGen and Nitrase Therapeutics Enter Research Agreement
•
China-based HitGen Inc. (SHA: 688222) announced a research agreement with US firm Nitrase Therapeutics, Inc. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis, and screening of DELs to discover compounds that bind to certain targets that are of interest to Nitrase. Under the terms…
